心肌缺血是導(dǎo)致心肌梗死的主要原因，還可繼發(fā)心肌缺血再灌注損傷。黃芪甲苷是黃芪干燥根中提取的四環(huán)三萜皂苷類化合物，具有多種活性，通過降低心肌細(xì)胞凋亡、降低氧化應(yīng)激反應(yīng)、降低心肌炎性損傷、延緩心肌重塑、抑制過度細(xì)胞自噬、維持內(nèi)源性能量代謝、促進(jìn)新生血管形成減輕心肌缺血再灌注損傷?？偨Y(jié)了黃芪甲苷對心肌缺血再灌注損傷保護(hù)作用的研究進(jìn)展，為黃芪甲苷的臨床運(yùn)用提供參考。

Myocardial ischemia is the main cause of myocardial infarction and can also lead to secondary myocardial ischemia-reperfusion injury. Astragaloside IV is a tetracyclic triterpenoid saponin compound extracted from dried roots of Astragali Radix, which has various activities. Astragaloside IV can alleviate myocardial ischemia-reperfusion injury by reducing myocardial cell apoptosis, lowering oxidative stress response, reducing myocarditis injury, delaying myocardial remodeling, inhibiting excessive cell autophagy, maintaining endogenous energy metabolism, and promoting neovascularization. This article summarizes the research progress on the protective effect of astragaloside IV against myocardial ischemia-reperfusion injury, providing reference for the clinical application of astragaloside IV.

R285.5;R972